 |
Trials |
A phase I, open label, dose escalating study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of ascending intravenous doses of catumaxomab in epithelial cancer patientsCancer type: Solide tumores Phase: I Principal Investigator: Mau-Sørensen Morten Country: DK Keywords: Denmark, Rigshospitalet, EpCam, immunotherapy, fusion-antibody, solid tumor Status: Completed Link to Clinicaltrials.gov: http://www.clinicaltrials.gov/ct2/show/NCT01320020?term=NCT01320020&rank=1 |